A nurse is collecting data on a client who has COPD. Which of the following findings should the nurse expect?

A. The spacer increases the amount of medication delivered to the oropharynx.

Spacers are designed to minimize the amount of medication deposited in the oropharynx (back of the throat) and reduce the risk of side effects such as oral thrush or hoarseness. The main purpose of using a spacer is to optimize the delivery of medication to the lungs.

B. The spacer increases the amount of medication delivered to the lungs.

When reinforcing teaching with the parents of a child who is starting to use a spacer with a metered-dose inhaler (MDI) to treat asthma, the nurse should include the information that the spacer increases the amount of medication delivered to the lungs. Spacers help improve the delivery of medication from the MDI to the lungs by reducing the need for coordination between actuation of the MDI and inhalation. They also slow down the speed of the aerosolized medication particles, allowing more time for them to be inhaled into the lungs effectively.

C. Inhale rapidly when using the spacer with the MDI.

Inhaling rapidly may lead to improper inhalation technique and reduce the effectiveness of medication delivery to the lungs. Instead, the child should be instructed to inhale slowly and deeply to ensure that the medication reaches the lower airways.

D. Cover exhalation slots of the spacer with lips when inhaling.

Covering the exhalation slots of the spacer with lips during inhalation is not recommended. These slots are designed to allow the child to exhale freely and prevent buildup of pressure within the spacer. Encouraging the child to exhale into the spacer would hinder proper inhalation technique and could lead to decreased medication delivery to the lungs.

A. Dry mouth

Dry mouth is a common adverse effect of ipratropium (Atrovent) due to its anticholinergic properties. Anticholinergic medications can inhibit saliva production, leading to a sensation of dryness in the mouth. While uncomfortable, dry mouth tends to improve over time as the body adjusts to the medication. Patients can manage dry mouth by increasing fluid intake and practicing good oral hygiene.

B. Anxiety

Anxiety is not a common adverse effect of ipratropium (Atrovent). While some individuals may experience anxiety as a side effect of certain medications, it is not typically associated with ipratropium. If a patient experiences anxiety while taking ipratropium, it is essential to assess whether it may be related to other factors or medications and to consult a healthcare provider for appropriate management.

C. Tachycardia

Tachycardia (rapid heart rate) is not a common adverse effect of ipratropium (Atrovent). While ipratropium is an anticholinergic medication that can affect heart rate in some individuals, tachycardia is not typically reported as a common side effect. However, patients should be monitored for changes in heart rate and other cardiovascular effects while taking ipratropium, especially if they have pre-existing cardiac conditions.

D. Urine retention

Urinary retention is a potential adverse effect of ipratropium (Atrovent) due to its anticholinergic properties. Anticholinergic medications can relax the smooth muscle of the bladder, leading to difficulty emptying the bladder completely. However, urinary retention is less common with ipratropium compared to other anticholinergic medications, such as those used to treat overactive bladder. Patients experiencing urinary retention while taking ipratropium should consult their healthcare provider for further evaluation and management.